Evidence map›Paper›PMID 38012333›Full record

Trial reportPsychopharmacology2024

A practice quit model to test early efficacy of medications for alcohol use disorder in a randomized clinical trial.

Lara A Ray, Wave-Ananda Baskerville, Steven J Nieto, Erica Grodin, Craig Enders, Annabel Kady, Lindsay Meredith, Artha Gillis, Adam Leventhal, Diana Ho and 1 more

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Psychopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Influence of sleep quality on lapse to alcohol use during a quit attempt.Alcohol and alcoholism (Oxford, Oxfordshire) · 2024
    Trial
  4. Article
  5. Who is alcohol cue-reactive? A machine learning approach.Alcohol and alcoholism (Oxford, Oxfordshire) · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Lara A RayDepartment of Psychology, University of California at Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA, 90095-1563, USA. lararay@psych.ucla.edu.ORCID http://orcid.org/0000-0002-5734-9444
Wave-Ananda BaskervilleDepartment of Psychology, University of California at Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA, 90095-1563, USA.
Steven J NietoDepartment of Psychology, University of California at Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA, 90095-1563, USA.
Erica GrodinDepartment of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles, Los Angeles, CA, USA.
Craig EndersDepartment of Psychology, University of California at Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA, 90095-1563, USA.
Annabel KadyDepartment of Psychology, University of California at Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA, 90095-1563, USA.
Lindsay MeredithDepartment of Psychology, University of California at Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA, 90095-1563, USA.
Artha GillisDepartment of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles, Los Angeles, CA, USA.
Adam LeventhalDepartment of Population and Public Health Sciences, University of Southern California, Los Angeles, CA, USA.
Diana HoDepartment of Psychology, University of California at Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA, 90095-1563, USA.
Karen MiottoDepartment of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles, Los Angeles, CA, USA.
University of California, Los Angeles · USUniversity of Southern California · US

Funding

UCLA Training Program in Translational Neuroscience of Drug Abuse (TNDA)T32DA024635 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LARA A. RAY, Kate M Wassum · 2008 to 2026
$6.2M
Clinical Neuroscience of Alcoholism: Integrating Neuroscience and Clinical TrialsK24AA025704 · NIAAA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LARA A. RAY · 2018 to 2026
$1.3M
A NOVEL HUMAN LABORATORY MODEL FOR SCREENING MEDICATIONS FOR ALCOHOL USE DISORDERR21AA027180 · NIAAA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RAY, LARA A. · 2019 to 2021
$540k
Integrating findings across stages of medication development for AUDR21AA029771 · NIAAA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RAY, LARA A. · 2021 to 2022
$438k
Applying behavioral economics to screen medications for alcohol use disorderF32AA029288 · NIAAA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NIETO, STEVEN J · 2021 to 2022
$115k
Neuroimmune Treatment for AUD: Testing Moderators of Clinical Response and Mechanisms of ActionF31AA029295 · NIAAA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MEREDITH BROUSSARD, LINDSAY · 2022 to 2023
$59k
NIAAA NIH HHS F31 AA029295NIAAA NIH HHS F32 AA029288NIAAA NIH HHS K24 AA025704NIAAA NIH HHS R21 AA027180NIAAA NIH HHS R21 AA029771NIDA NIH HHS T32 DA024635
6 · The paper itself

Abstract

rationaleScreening novel medications for alcohol use disorder (AUD) requires models that are both efficient and ecologically-valid. Ideally, such models would be associated with the outcomes of a given medication in clinical trials.

objectivesTo test a novel human laboratory model in which individuals with intrinsic motivation to change their drinking engage in a "practice quit" attempt consisting of 6 days of complete abstinence from alcohol.

methodIndividuals with current AUD completed a randomized, double-blind, placebo-controlled study of naltrexone (50 mg), varenicline (2 mg bid), or matched placebo. Participants were titrated onto the study medication for 1 week prior to starting the 6-day practice quit attempt. During the practice quit attempt, participants completed daily interviews with research staff. All participants completed an alcohol cue-exposure paradigm before starting the study medication and after 2 weeks of study medication.

resultsThere were no significant medication effect on drinks per drinking day (F(2,49) = 0.66, p = 0.52) or percent days abstinent (F(2,49) = 0.14, p = 0.87) during the 6-day practice quit period. There were no medication effects on alcohol cue-reactivity (F(2,44) = 0.80, p = 0.46). Notably, participants sharply reduced their drinking during the entire 13-day medication treatment period, as compared to reducing only during the 6-day practice quit period. During the total medication period, higher levels of motivation to change was associated with higher percent days abstinent (F(1,49) = 8.12, p < 0.01).

conclusionsThis study reports mostly null findings, which challenges us to decompose its nuanced design to consider model refinements. Possible changes to the model include considering the requirement for intrinsic motivation for change, including a longer practice quit period, encompassing the medication administration timeframe in the practice quit period, increasing the required sample size for signal detection, and examining a post COVID-19 pandemic cohort.

Indexed as

AlcoholismAlcohol DrinkingEthanolHumansNaltrexonePandemicsVareniclineEthanolNaltrexoneVareniclineAlcohol use disorderCue-reactivityNaltrexonePharmacotherapyVarenicline

Identifiers

PMID38012333
PMCPMC11927384
OpenAlexW4389082336

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.